Europe Diabetes Care Devices Market size to cross USD 44.5 Billion by 2034

Selbyville, DE. - Europe diabetes care devices market was estimated at USD 14.5 billion in 2024 and is expected to grow from USD 16 billion in 2025 to USD 44.5 billion by 2034, at a CAGR of 12%, according to the latest report published by Global Market Insights Inc. 

Alongside this, modern sedentary lifestyles marked by reduced physical activity and poor dietary habits, such as high consumption of processed foods and sugars, are contributing to a growing number of new diabetes diagnoses. As more people live with diabetes, there is a heightened need for reliable, easy-to-use devices that help patients monitor and manage their blood glucose levels effectively.

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 14.5 billion
  
• 2025 Market Size: USD 16 billion
  
• 2034 Forecast Market Size: USD 44.5 billion
  
• CAGR (2025–2034): 12%
  

Regional Insights:

• Largest Market: Germany
  
• Fastest Growing Market: UK
  
• Emerging Countries: France, Italy, Spain
  
  

Key Growth Drivers:

1. Shift toward home-based and remote monitoring: The growing emphasis on self-management and remote patient monitoring is boosting the adoption of blood glucose monitors, insulin pens, and continuous glucose monitoring (CGM) systems for at-home use.
   
2. Technological advancements in device innovation: Manufacturers are investing in next-generation devices with features like Bluetooth connectivity, smartphone integration, real-time glucose tracking, and closed-loop insulin delivery systems, enhancing user convenience and accuracy.
   
3. Supportive government policies and reimbursement structures: European healthcare systems, particularly in countries like Germany, France, and the UK, offer strong reimbursement support for diabetes devices, encouraging wider adoption among patients and providers.
   
4. Increasing awareness and early diagnosis initiatives: Public health campaigns and screening programs focused on early diabetes detection are leading to increased diagnosis rates and timely intervention, driving demand for monitoring and insulin delivery devices.
   
5. Growing use of wearable and non-invasive technologies: Patient preference is shifting toward discreet, wearable devices that offer continuous monitoring without the discomfort of frequent finger pricks, accelerating the adoption of CGMs and patch-based systems.
   
   

Key Players:

• Abbott Laboratories led the market with over 11.2% share in 2024.
  
• Some of the top players in this market include Ascensia Diabetes Care, Dexcom, Medtronic, Abbott Laboratories, and F. Hoffmann-La Roche, which together held a 25% share in 2024.
  
  

Key Challenges

1. High cost of advanced devices: While continuous glucose monitors (CGMs), insulin pumps, and smart insulin pens offer superior management, their high upfront and maintenance costs remain a barrier, especially in regions with limited reimbursement or out-of-pocket healthcare models.
   
2. Uneven reimbursement landscape across countries: Reimbursement policies for diabetes care devices vary significantly across Europe, creating inconsistencies in access.
   
3. Data privacy and regulatory complexities: With the rise of connected devices and digital health platforms, compliance with stringent EU data protection laws (like GDPR) adds complexity for manufacturers and healthcare providers, especially when integrating patient data across systems.
   
4. Limited awareness in underserved regions: In parts of Eastern and Southern Europe, a lack of awareness about early detection and advanced diabetes management tools leads to delayed diagnoses and the underuse of modern care technologies.
   
5. Resistance to technology adoption among older patients: Many elderly diabetes patients still prefer traditional methods over digital solutions due to a lack of familiarity, fear of technology, or physical limitations, slowing the adoption of newer, more efficient devices.
   

Browse key industry insights spread across 110 pages with 350 market data tables and figures from the report, “Europe Diabetes Care Devices Market - By Product, By End Use - Regional Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/europe-diabetes-care-devices-market

Rising Adoption of Devices

The devices segment held a significant share in 2024, as patients and providers increasingly rely on advanced tools for accurate glucose monitoring and effective insulin delivery. This segment includes a wide range of products such as blood glucose meters, continuous glucose monitors (CGMs), smart insulin pens, and insulin pumps, each playing a vital role in day-to-day disease management. The growing availability of connected devices that integrate with mobile apps and cloud-based systems is transforming how patients track and share their health data.

Homecare to Gain Traction

The homecare segment generated robust revenues in 2024, fueled by rising patient preference for self-management and the broader shift toward decentralized healthcare in Europe. With diabetes requiring continuous monitoring and lifestyle adjustments, more patients are seeking solutions that allow for flexible, at-home disease management. The adoption of CGMs, portable insulin pumps, and digital health platforms is making it easier for individuals to monitor their glucose levels without frequent clinical visits.

Germany to Emerge as a Propelling Region

Germany diabetes care devices market held a sizeable share in 2024, supported by a robust healthcare system, high public awareness, and widespread access to advanced medical technologies. Germany’s progressive reimbursement policies, particularly for CGMs and insulin pumps, continue to drive demand among both type 1 and type 2 diabetes patients. Additionally, strong physician advocacy for digital tools and early intervention strategies is fueling device adoption.

Major players in the Europe diabetes care devices market are DarioHealth, Medtronic, Ypsomed Holding, F. Hoffmann-La Roche, ARKRAY, Insulet, Sanofi, Dexcom, Nova Biomedical, Novo Nordisk, Ascensia Diabetes Care, Dr. Reddy’s Laboratories, B. Braun Melsungen, Abbott Laboratories, Eli Lilly and Company, Bionime, Becton, Dickinson and Company.

To strengthen their foothold in the Europe diabetes care devices market, companies are implementing strategies that focus on innovation, partnerships, and regional expansion. Leading manufacturers are investing heavily in R&D to create integrated systems combining glucose monitoring, insulin delivery, and AI-driven insights. Strategic collaborations with digital health startups are helping bring data analytics and real-time tracking features into legacy devices.